Sign In
Buy LFCR
$5.67
+0.220 (+4.04%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company")
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation
03:00pm, Wednesday, 11'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company")
Lifecore Biomedical: An Interesting CDMO Pure Play
10:40am, Sunday, 01'st Dec 2024
Lifecore, a leading CDMO, specializes in sterile injectable pharmaceuticals and is poised to benefit from the growing CDMO market and potential GLP-1 opportunities. The company is doubling production
Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
04:05pm, Tuesday, 26'th Nov 2024
Three-Year Term Extension Combined with Simplification and Reduction of Interest Rates Helps Further Strengthen Company's Balance Sheet and Overall Financial Position
Lifecore Biomedical Hosts Virtual Investor Day
04:17pm, Thursday, 21'st Nov 2024
CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Lifecore Biomedical to Present at Stephens Annual Investment Conference
04:05pm, Tuesday, 12'th Nov 2024
CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024
07:00am, Thursday, 07'th Nov 2024
CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations
07:00am, Monday, 04'th Nov 2024
Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity
SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer
Lifecore Biomedical, Inc. (LFCR) Q1 2025 Earnings Call Transcript
10:59am, Friday, 04'th Oct 2024
Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q1 2025 Earnings Call Transcript October 4, 2024 8:30 AM ET Company Participants Stephanie Diaz - Manager of IR Paul Josephs - President and CEO Ryan Lake - CF
Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update
07:30am, Friday, 04'th Oct 2024
-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with New and Existing Customers --
Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock
07:20am, Friday, 04'th Oct 2024
PIPE with New and Existing Investors Supports Working Capital and Operations PIPE with New and Existing Investors Supports Working Capital and Operations
Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024
04:05pm, Thursday, 03'rd Oct 2024
CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Multi-Million Dollar Development Agreement Establishes Lifecore as Lindy Biosciences' Preferred CDMO
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
11:00am, Saturday, 28'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("
